Ibrutinib for the treatment of mantle cell lymphoma

Expert Review of Hematology

Volumn 7, Issue 5, 2014, Pages 521-531

  Shah, Nimish ^a,b   Hutchinson, Claire ^a,b   Rule, Simon ^a,b  

^a DERRIFORD HOSPITAL   (United Kingdom)

^b UNIVERSITY OF PLYMOUTH   (United Kingdom)

Author keywords

Bruton's tyrosine kinase inhibitor; ibrutinib; mantle cell lymphoma

Indexed keywords

BRUTON TYROSINE KINASE; BRUTON TYROSINE KINASE INHIBITOR; IBRUTINIB; AGAMMAGLOBULINAEMIA TYROSINE KINASE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE; RITUXIMAB;

ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CONTROL; CANCER SURVIVAL; CELL PROLIFERATION; DISEASE COURSE; DRUG SAFETY; DRUG TOLERABILITY; ENZYME STRUCTURE; HUMAN; LONG TERM CARE; MANTLE CELL LYMPHOMA; PHASE 2 CLINICAL TRIAL (TOPIC); SIGNAL TRANSDUCTION; STANDARD; ADULT; AGED; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL (TOPIC); HALF LIFE TIME; HEMATOLOGIC DISEASES; IMMUNOTHERAPY; LYMPHOMA, MANTLE-CELL; METABOLISM; MIDDLE AGED; PHOSPHORYLATION; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; HALF-LIFE; HEMATOLOGIC DISEASES; HUMANS; IMMUNOTHERAPY; LYMPHOMA, MANTLE-CELL; MIDDLE AGED; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRAZOLES; PYRIMIDINES; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 84907042192     PISSN: 17474086     EISSN: 17474094     Source Type: Journal    
DOI: 10.1586/17474086.2014.951323     Document Type: Article

References (74)

1. Jares P, Colomer D, Campo E. Molecular pathogenesis of mantle cell lymphoma. J Clin Invest 2012;122(10):3416-23
2. Zhou Y, Wang H, Fang W. Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004. Cancer 2008;113(4):791-8
3. McKay P, Leach M, Jackson R, et al. Guidelines for the investigation and management of mantle cell lymphoma. Br J Haematol 2012;159(4):405-26
4. Eve H, Furtado M, Hamon M, Rule S. Time to treatment does not influence overall survival in newly diagnosed mantle-cell lymphoma. J Clin Oncol 2009; 27(32):189-90
5. Hsi ED, Martin P. Indolent mantle cell lymphoma. Leuk Lymphoma 2013;55(4): 761-7
6. Martin P, Chadburn A, Christos P. Outcome of deferred initial therapy in mantle-cell lymphoma. J Clin Oncol 2009; 27(8):1209-13
7. Vose JM. Mantle cell lymphoma: 2013 Update on diagnosis, risk-stratification, and clinical management. Am J Hematol 2013;88(12):1082-8
8. Merli F, Luminari S, Ilariucci F, et al. Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi. Br J Haematol 2012;156(3):346-53
9. Geisler CH, Kolstad A, Laurell A, et al. Nordic MCL2 trial update: six-year followup after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur. Br J Haematol 2012; 158(3):355-62
10. Navarro A, Clot G, Royo C, et al. Molecular subsets of mantle cell lymphoma defined by the IGHV mutational status and SOX11 expression have distinct biologic and clinical features. Cancer Res 2012; 72(20):5307-16
11. Rickert R. New insights into pre-BCR and BCR signalling with relevance to C cell malignancies. Nature 2013;13(8):578-91
12. Brett LK, Williams ME. Current and emerging therapies in mantle cell lymphoma. Curr Treat Options Oncol 2013;14(2):198-211
13. Mohamed A, Yu L, Backesjo C, et al. Bruton's tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain. 2009;228(1): 58-73
14. Buggy JJ. Bruton tyrosine kinase (BTK) and its role in B-cell malignancy. Int Rev Immunol 2012;32(2):119-32
15. Satterthwaite AB, Witte ON. The role of Bruton's tyrosine kinase in B-cell development and function: a genetic perspective. 2000;175:120-7
16. Bruton O. Agammaglobulinemia. Pediatrics 1998;102(1 Pt 2):213-15
17. Ponader S. Burger J a. Bruton's Tyrosine Kinase: from X-Linked Agammaglobulinemia Toward Targeted Therapy for B-Cell Malignancies. J Clin Oncol 2014;32(17):1830-9
18. Choi M, Kipps T. Inhibitors of B-cell receptor signaling for patients with B-cell malignancies. Cancer J 2013;18(5):404-10
19. Burger JA, Buggy JJ. Emerging drug profiles; Bruton's Tyrosine kinase (BTK) inhibitor ibrutinib (PCI-32765). Leuk Lymphoma 2013;54(11):2385-91
20. Baba Y, Hashimoto S, Matsushita M, et al. BLNK mediates Syk-dependent Btk activation. Proc Natl Acad Sci USA 2001; 98(5):2582-6
21. Psyrri A, Papageorgiou S, Liakata E, et al. Phosphatidylinositol 3'-kinase catalytic subunit alpha gene amplification contributes to the pathogenesis of mantle cell lymphoma. Clin Cancer Res 2009;15(18): 5724-32
22. Wiestner A. Targeting B-Cell receptor signaling for anticancer therapy: the Bruton's tyrosine kinase inhibitor ibrutinib induces impressive responses in B-cell malignancies. J Clin Oncol 2013;31(1): 128-30
23. Niemann CU, Wiestner A. B-cell receptor signaling as a driver of lymphoma development and evolution. Semin Cancer Biol 2013;23(6):410-21
24. Advani RH, Buggy JJ, Sharman JP, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol 2013;31(1): 88-94
25. Cinar M, Hamedani F, Mo Z, et al. Bruton tyrosine kinase is commonly overexpressed in mantle cell lymphoma and its attenuation by Ibrutinib induces apoptosis. Leuk Res 2013;37(10):1271-7
26. Beà S, Valdés-Mas R, Navarro A, et al. Landscape of somatic mutations and clonal evolution in mantle cell lymphoma. Proc Natl Acad Sci USA 2013;110(45):18250-5
27. Pighi C, Gu T-L, Dalai I, et al. Phospho-proteomic analysis of mantle cell lymphoma cells suggests a pro-survival role of B-cell receptor signaling. Cell Oncol (Dordr) 2011;34(2):141-53
28. Hadzidimitriou A, Agathangelidis A, Darzentas N, et al. Is there a role for antigen selection in mantle cell lymphoma? Immunogenetic support from a series of 807 cases. Blood 2011;118(11):3088-95
29. Rinaldi A, Kwee I, Taborelli M, et al. Genomic and expression profiling identifies the B-cell associated tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphoma. Br J Haematol 2006;132(3): 303-16
30. Honigberg LA, Smith AM, Sirisawad M, et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci USA 2010;107(29):13075-80
31. Bhatt V, Alejandro L, Michael A, Ganetsky A. The promising impact of ibrutinib, a Bruton's tyrosine kinase inhibitor, for the management of lymphoid malignancies. Pharmacotherapy 2013;34(3): 303-14
32. Maddocks K, Blum KA. Ibrutinib in B-cell Lymphomas. Curr Treat Options Oncol 2014;15(2):226-37
33. Wang ML, Rule S, Martin P, et al. Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma. N Engl J Med 2013;369(6):507-16
34. Farooqui M, Lozier J, Valdez J, et al. Ibrutinib (PCI 32765) rapidly improves platelet counts in chronic lymphocytic leukemia/ small lymphocytic lymphoma (CLL/SLL) patients and has minimal effects on platelet aggregation. Blood 2012;120: abstract 1789
35. Chang BY, Francesco M, De Rooij MFM, et al. Egress of CD19(+)CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients. Blood 2013;122(14):2412-24
36. Cameron F, Sanford M. Ibrutinib: first global approval. Drugs 2014;74(2):263-71
37. Blum KA, Christian B, Flynn J, et al. A phase I trial of the Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib (PCI- 32765), in combination with rituximab (R) and bendamustine in patients with relapsed/ refractory non-Hodgkin's. Am Soc Hematol 2012;21(3):1643
38. Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 2013;381(9873):1203-10
39. ClinicalTrials. gov. A study of the Bruton's tyrosine kinase inhibitor ibrutinib given in combination with bendamustine and rituximab in patients with newly diagnosed mantle cell lymphoma. Available from: http://www. clinicaltrials. gov/show/ NCT01776840
40. Flinn IW, Berdeja J, Freidbery J, et al. Combining ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP): updated results from a phase 1b study in treatment-naïve patients with CD20-positive B-Cell Non-Hodgkin's lymphoma (NHL). Blood 2013;122(21):852
41. ClinicalTrials. gov. A study combining ibrutinib. with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with CD20-positive B-cell non Hodgkin lymphoma. Available from: http:// clinicaltrials. gov/show/NCT01569750
42. Akinleye A, Chen Y, Mukhi N, et al. Ibrutinib and novel BTK inhibitors in clinical development. J Hematol Oncol 2013;6(1):59
43. Aalipour A, Advani RH. Bruton tyrosine kinase inhibitors: a promising novel targeted treatment for B cell lymphomas. Br J Haematol 2013;163(4):436-43
44. Middendorp S, Dingjan GM, Maas A, et al. Function of Bruton's tyrosine kinase during B cell development is partially independent of its catalytic activity. J Immunol 2003;171:5988-96
45. Yasuhiro T, Yoshizawa T, Daub H, et al. ONO-WG- 307, a novel, potent and selective inhibitor of Bruton's tyrosine kinase (Btk), results in sustained inhibition of the ERK, AKT and PKD signaling pathways. Cancer Res 2012;72:abstract 2021
46. Kozaki R, Yoshizawa T, Yasuhiro T, et al. Development of a Bruton's tyrosine kinase (Btk) inhibitor - ONO-WG-307, a potential treatment for B-cell malignancies. AACR 2012;857:abstract 857
47. Rule S, Shah N, Salles G, et al. A phase I study of the oral Btk inhibitor ONO-4059 in patients with relapsed/ refractory B-cell lymphoma. Blood 2013; 122(21):abstract 4397
48. Salles G, Karlin L, Rule S, et al. A phase I study of the oral Btk inhibitor ONO-4059 in patients with relapsed/ refractory and high risk chronic lymphocytic leukaemia (CLL). Blood 2013;122(21): abstract 676
49. Evans E, Tester R, Aslanian S, et al. Clinical development of AVL-292; a potent, selective covalent Btk inhibitor for the treatment of B cell malignancies. Blood 2011;118(21):3485
50. Brown J, Harb W, Hill H, et al. Phase Ib trial of AVL-292, a covalent inhibitor of Bruton's tyrosine kinase (Btk), in chronic lymphocytic leukemia (CLL) and B-non-Hodgkin lymphoma (B-NHL). Blood 2013;122(21):abstract 1630
51. ClinicalTrials. gov. A phase IB study Of The BTKi CC-292 combined with lenalidomide in adults patients with relapsed/refractory B-Cell lymphoma (CLEAR). Available from: http://clinicaltrials. gov/show/ NCT01766583
52. Uckun F, Zheng Y, Cetkovic-Cvrlje M, et al. In vivo pharmacokinetic features, toxicity profile, and chemosensitizing activity of alpha-cyano-beta-hydroxybetamethyl- N-(2,5-dibromophenyl) propenamide (LFM-A13), a novel antileukemic agent targeting Bruton's tyrosine kinase. Clin Cancer Res 2002;8(5): 1224-33
53. Uckun F, Dibirdik I, Qazi S, et al. Anti-breast cancer activity of LFM-A13, a potent inhibitor of Polo-like kinase (PLK). Bio Org Med Chem 2007;15(2):800-14
54. Mahajan S, Ghosh S, Sudbeck E, et al. Rational design and synthesis of a novel anti-leukemic agent targeting Bruton's tyrosine kinase (BTK), LFM-A13 [alphacyano- beta-hydroxy-betamethyl- N-(2, 5- dibromophenyl)propenamide]. J Biol Chem 1999;274(14):9587-99
55. ClinicalTrial. gov. Safety, PK/PD, food effect study of orally administered HM71224 in healthy adult male volunteers. Available from: http://clinicaltrials. gov/show/ NCT01765478
56. Hess G, Herbrecht R, Romaguera J, et al. Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol 2009; 27(23):3822-9
57. Goy A, Sinha R, Williams ME, et al. Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study. J Clin Oncol 2013;31(29):3688-95
58. ClinicalTrials. gov. Study of ibrutinib (a Bruton's tyrosine kinase inhibitor), versus temsirolimus in patients with relapsed or refractory mantle cell lymphoma who have received at least one prior therapy. Available from: http://clinicaltrials. gov/show/ NCT01646021
59. O'Brien S, Furman RR, Coutre SE, et al. Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial. Lancet Oncol 2014;15(1):48-58
60. Hermine O, Hoster E, Walewski J, et al. Alternating courses of 3x CHOP and 3x DHAP plus rituximab followed by a high dose ARA-C containing myeloablative regimen and autologous stem cell transplantation (ASCT). Increases Overall Survival When Compared to 6 Courses of CHOP Plus Rituximab Followed by Myeloablative Radiochemotherapy and ASCT in Mantle Cell Lymphoma: Final analysis of the MCL younger trial of the European mantle cell lymphoma network (MCL net) Blood 2012;120(21):abstract 151
61. Dreyling M, Lenz G, Hoster E, et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European. Blood 2005;105(7):2677-84
62. Pérez-Galán P, Dreyling M, Wiestner A. Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era. Blood 2011; 117(1):26-38
63. Zucca E, Bertoni F. Toward new treatments for mantle-cell lymphoma? N Engl J Med 2013;369(6):571-2
64. ClinicalTrials. gov. Rituxan/bendamustine/ PCI-32765 in relapsed DLBCL, MCL, or indolent non-Hodgkin's lymphoma. Available from: http://clinicaltrials. gov/show/ NCT01479842
65. ClinicalTrials. gov. A long-term extension study of PCI-32765 (ibrutinib). Available from: http://clinicaltrials. gov/show/ NCT01804686
66. ClinicalTrials. gov. Phase 2 ibrutinib + rituximab in relapsed/ refractory mantle cell lymphoma (R/R MCL). Available from: http://clinicaltrials. gov/show/NCT01880567
67. ClinicalTrials. gov. Ublituximab + ibrutinib in select B-cell malignancies. Available from: http://clinicaltrials. gov/show/NCT02013128
68. ClinicalTrials. gov. Lenalidomide and ibrutinib in treating patients with relapsed or refractory B-cell non-Hodgkin lymphoma. Available from: http:// clinicaltrials. gov/show/NCT01955499
69. Goy A, Bernstein SH, Kahl BS, et al. Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study. Ann Oncol 2009;20(3):520-5
70. Kouroukis C, Belch A, Crump M, et al. Flavopiridol in untreated or relapsed mantle-cell lymphoma: results of a phase II study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2003;21(9):1740-5
71. Renner C, Zinzani PL, Gressin R, et al. A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma. Haematologica 2012;97(7): 1085-91
72. Witzig TE, Reeder CB, LaPlant BR, et al. A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma. Leukemia 2011;25(2):341-7
73. Eve HE, Carey S, Richardson SJ, et al. Single-agent lenalidomide in relapsed/ refractory mantle cell lymphoma: results from a UK phase II study suggest activity and possible gender differences. Br J Haematol 2012;159(2):154-63
74. Ghielmini M, Schmitz SFH, Cogliatti S, et al. Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK). J Clin Oncol 2005;23(4):705-11.